VANCOUVER, BRITISH COLUMBIA--(Marketwire - Jan. 30, 2008) - ALDA Pharmaceuticals Corp. (TSX VENTURE:APH) ("ALDA") announces that it has received further clinical testing results from BioScience Laboratories, Inc. for the T36® formulation ("T36®"). Complete efficacy was achieved against Candida albicans by T36® within the shortest time required by the FDA, Health Canada and the European Medicines Agency. C. albicans is a major cause of yeast infections which account for one-third of all vulvovaginal infections ("VVI's"). Bacteria are a second major cause of VVI's and combinations of bacteria and fungi cause most of the remaining cases. The effectiveness that T36® has demonstrated against both fungi and bacteria provides important evidence that ALDA's T36® VVI Treatment will provide an effective means to treat all types of VVI's.
